GlobeNewswire Inc.··NaINmune Bio's Alzheimer's Drug Shows Promise in Phase 2 Trial, Earns FDA Fast Track Status
INmune Bio ($INMB) published Phase 2 MINDFuL trial results showing XPro™ cognitive benefits in early Alzheimer's patients with inflammation markers.
INMBphase 2 trialAlzheimer's disease